These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35771139)

  • 1. DNA methylation-regulated SNX20 overexpression correlates with poor prognosis, immune cell infiltration, and low-grade glioma progression.
    Chen X; Jiang X; Wang H; Wang C; Wang C; Pan C; Zhou F; Tian J; Niu X; Nie Z; Chen W; Huang X; Pu J; Li C
    Aging (Albany NY); 2022 Jun; 14(12):5211-5222. PubMed ID: 35771139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCAPG2 Is a Novel Prognostic Biomarker and Promotes Cancer Stem Cell Maintenance in Low-Grade Glioma.
    Ren W; Yang S; Chen X; Guo J; Zhao H; Yang R; Nie Z; Ding L; Zhang L
    Front Oncol; 2022; 12():918606. PubMed ID: 35898895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
    BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
    Ma W; Mei P
    World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.
    Liu F; Tu Z; Liu J; Long X; Xiao B; Fang H; Huang K; Zhu X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34988580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.
    Lu Y; Chang P; Bian J; Zhu L
    Cancer Biomark; 2023; 38(3):393-407. PubMed ID: 37955080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
    Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
    Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
    Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
    Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma.
    Wang H; Wang X; Xu L; Zhang J
    Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.
    Su X; Liu J; Tu Z; Ji Q; Li J; Liu F
    Transl Cancer Res; 2024 Apr; 13(4):1786-1806. PubMed ID: 38737693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N6-Methylandenosine-Related Gene
    Jiang X; Shi Y; Chen X; Xu H; Huang X; Li L; Pu J
    Front Mol Biosci; 2022; 9():773662. PubMed ID: 35309512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.